All News
#ACR21 Ab#1445. RTX & #covid19 outcomes
⭐️RTX ass. w/ Upwards arrow COVID hospitalization, ICU admission, and ventilation
▶️We need huge caution in pts that have not been vax'ed before RTX 💉💉
@Rheumnow
https://t.co/6UNUVhnBkI https://t.co/vHkQe9fZpI
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 Ab#1036.
Rheum is often the field of uncertainty. @zach_wallace_md shows uncertainty correlates w/ depression, anxiety, sickness impact across rheum diseases
⭐️Is uncertainty something to target as intervention?
@Rheumnow https://t.co/v9kbk2hCqO https://t.co/50ELS3ZQp9
Links:
Eric Dein ericdeinmd ( View Tweet)
So what do we do with Iberdomide data? Tough to analyze re 2nd half of yr1 and uncertainty of dose response Abst#1458 #ACR21 @RheumNow v low placebo response 35% Interesting https://t.co/JXnoJTy2tv
Janet Pope Janetbirdope ( View Tweet)
Among 6 CV risk algorithms, the best to predict the carotid plaque (CP) in PsA is the ACC/AHA risk score showed an AUC 0.681 (0.551-0.812), p=0.008, a cut-off point ≥4.8, sensitivity of 63.6%, and specificity of 64.4%
⭐️Prevalence CP 42.3%
Abst #1315 #ACR21 @RheumNow https://t.co/hRvyjetYq3
swethaann23 swethaann23 ( View Tweet)
I thought pirfenidone was just an anti-fibrotic - the spectrum of its MOA is actually fascinating
@ErinWilfongMD #ACR21 Antifibrotics session, chaired by @JuliePaikMD @RheumNow https://t.co/oMZOtfAUq0
David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
DCVAS testing results in GCA. @davidliew @philipcrobinson are you guys essentially not imaging anyone in anyway? What's going on? #ACR21 @RheumNow https://t.co/IMr5ee2Iea
Richard Conway RichardPAConway ( View Tweet)
Billing and coding expert, Jean Acevedo shares the three URLs that you need to best understand the updated 2021 EM coding! #ACR21 @RheumNow #RheumNow https://t.co/3HbDuZP8gC
Dr. Rachel Tate uptoTate ( View Tweet)
Pulmonary Arterial Hypertension in #AOSD
Rare but severe complication - life threatening
French study of 13 pts - network dataset. ALL FEMALES!
Age 32, mean f/u 34 mths, 5 pts (38.5%) DIED
@RheumNow #ACRBest abst#1100 https://t.co/5LIzHagesP
Bella Mehta bella_mehta ( View Tweet)
Towards better assessment and management of multimorbidity by Dr. Mrinalini Dey ( @DrMiniDey ) #ACR21
https://t.co/7DPGsVB6bG https://t.co/F57k44AWZ4
Links:
Dr. John Cush RheumNow ( View Tweet)
Knowledge Bowl at #ACR21
⭐️Approximately half of patients with IIM who develop pneumomediastinum have this subtype of dermatomyositis.
➡️Amyopathic (MDA5) dermatomyositis
@RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Knowledge Bowl at #ACR21
⭐️In a suspected PAN case, you order a peripheral smear to look for this potential etiology,
➡️Hairy cells
@RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
JAK-pot registry-based study. Following JAKi failure should you switch mode of action or go to second JAKi? Both seem equally effective in terms of drug retention. Didn't matter if switch for efficacy or adverse event. Abstr#1442 #ACR21 @RheumNow https://t.co/QEBB3flArC
Richard Conway RichardPAConway ( View Tweet)
#ACR21 Abs#1442: JAKpot - Cycle JAK or switch to bDMARD after JAK failure?
▶️No difference between cycle vs bDMARD group
▶️Non-signif trends: cycled JAK better for inefficacy to 1st JAK, bDMARD better for adverse effects
@Rheumnow https://t.co/6UNUVh5ZW8 https://t.co/upfI6tDH1p
Links:
Eric Dein ericdeinmd ( View Tweet)
First JAKi failure: What's next? Wanna find out? It's here
https://t.co/o5CE1MBzUu
Abstr#1442 #ACR21 @RheumNow https://t.co/f0sdPn5mcZ
Aurelie Najm AurelieRheumo ( View Tweet)
Trauma associates with subsequent increased flares of SLE. Abstr#1446 #ACR21 @RheumNow https://t.co/QeNXOjHAjn
Richard Conway RichardPAConway ( View Tweet)
Tell me there's no collegiality on the #ACR21 virtual platform!
kudos to @ACRheum for making this thing run so smoothly, year-on-year
(and I'm telling you, the value's in the chat and the questions)
@RheumNow @Janetbirdope https://t.co/XJZArHIdnc
David Liew drdavidliew ( View Tweet)
Can you win the JAK pot twice? Equal effectiveness of JAK to JAK in #RheumatoidArthritis vs JAK to bDMARD. If d/c due to AE w JAK seemed to recur w 2nd JAK. Not RCT ?Channeling bias. But JAKi were worse off at baseline but did= switch v swap #ACR21 #ACRBest abst#1442 @RheumNow https://t.co/SRXMHdUBJF
Janet Pope Janetbirdope ( View Tweet)
Dr Jafarzadeh @Tuhina_Neogi on association NSAID use with TKR. At same level of pain, NSAID users appear to have more TKR. Is this same phenomenon we see with IA steroids (and tanezumab?)⬇️pain⬆️use⬆️damage? Abstr#1447 #ACR21 @RheumNow https://t.co/oY2ckmui0D
Richard Conway RichardPAConway ( View Tweet)
Long-term follow up of REDO study of ultra-low dose RTX (200mg vs 500mg vs 1000mg every 6 months) in RA. All doses appeared similarly effective, but also had similar adverse events. Potentially cost and time saving. Abstr#1443 #ACR21 @RheumNow https://t.co/0FRYPUOMpY
Richard Conway RichardPAConway ( View Tweet)